Bufexamac

• CAT Number: A000790
• CAS Number: 2438-72-4
• Molecular Formula: C12H17NO3
• Molecular Weight: 223.27
• Purity: ≥95%
• Synonyms: 2438-72-4; Bufexamic acid; Parfenac; 2-(4-Butoxyphenyl)-N-hydroxyacetamide; Droxaryl
• Target: Epigenetics
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• InChI: 1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
• InChIKey: MXJWRABVEGLYDG-UHFFFAOYSA-N
• SMILES: CCCCOC1=CC=C(C=C1)CC(=O)NO

Bufexamac, also known as Droxaryl and CP-1044-J-3, is a benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. Bufexamac is used to treat various skin disorders.

Reference

1: Xiao Q, Dong N, Yao X, Wu D, Lu Y, Mao F, Zhu J, Li J, Huang J, Chen A, Huang
L, Wang X, Yang G, He G, Xu Y, Lu W. Bufexamac ameliorates LPS-induced acute lung
injury in mice by targeting LTA4H. Sci Rep. 2016 Apr 29;6:25298. doi:
10.1038/srep25298. PubMed PMID: 27126280; PubMed Central PMCID: PMC4850449.

2: Pan Y, Nixon R. Allergic contact dermatitis to topical preparations of
bufexamac. Australas J Dermatol. 2012 Aug;53(3):207-10. doi:
10.1111/j.1440-0960.2012.00876.x. Epub 2012 Mar 2. PubMed PMID: 22881467.

3: Nakada T, Matsuzawa Y. Allergic contact dermatitis syndrome from bufexamac for
nursing infant. Dermatitis. 2012 Jul-Aug;23(4):185-6. doi:
10.1097/DER.0b013e318260d774. PubMed PMID: 22828265.

4: Fukuda H, Sato Y, Usami N, Yokouchi Y, Mukai H. Contact dermatitis caused by
bufexamac sparing the eruption of herpes zoster. J Dermatol. 2012
Apr;39(4):405-7. doi: 10.1111/j.1346-8138.2011.01261.x. Epub 2011 Sep 27. PubMed
PMID: 21950459.

5: Seto Y, Ochi M, Igarashi N, Inoue R, Oishi A, Toida T, Yamada S, Onoue S. In
vitro photobiochemical characterization of sulfobutylether-β-cyclodextrin
formulation of bufexamac. J Pharm Biomed Anal. 2011 Jun 1;55(3):591-6. doi:
10.1016/j.jpba.2011.02.025. Epub 2011 Feb 26. PubMed PMID: 21429689.

6: Uter W, Schnuch A. EMA revokes marketing authorization for bufexamac. Contact
Dermatitis. 2011 Apr;64(4):235-6. doi: 10.1111/j.1600-0536.2011.01883.x. PubMed
PMID: 21392031.

7: Waltermann K, Marsch WCh, Kreft B. [Bufexamac-induced pigmented purpuric
eruption]. Hautarzt. 2009 May;60(5):424-7. doi: 10.1007/s00105-008-1656-2.
German. PubMed PMID: 19093092.

8: Belhadjali H, Ghannouchi N, Njim L, Mohamed M, Moussa A, Bayou F, Chakroun M,
Zakhama A, Zili J. Acute generalized exanthematous pustulosis induced by
bufexamac in an atopic girl. Contact Dermatitis. 2008 Apr;58(4):247-8. doi:
10.1111/j.1600-0536.2007.01271.x. PubMed PMID: 18353041.

9: Marttinen PH, Raulo SM, Suominen MM, Tulamo RM. Changes in MMP-2 and -9
activity and MMP-8 reactivity after amphotericin B induced synovitis and
treatment with bufexamac. J Vet Med A Physiol Pathol Clin Med. 2006
Aug;53(6):311-8. PubMed PMID: 16901276.

10: Schnuch A, Gefeller O, Uter W. [A common and insidious side-effect: allergic
contact dermatitis caused by bufexamac used in the treatment of dermatitis.
Results from the Information Network of Departments of Dermatology (IDVK)]. Dtsch
Med Wochenschr. 2005 Dec 16;130(50):2881-6. German. PubMed PMID: 16342011.